Original article: High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting

J. Herrstedt*, J. Hannibal, J. Hallas, E. Andersen, L. C. Laursen, M. Hansen

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstract

    Summary: In a randomized double-blind, cross-over trial of 34 patients receiving cisplatin-based chemotherapy (20-100 mg/m2), the antiemetic effect of high-dose metoclopramide (HDM) (10 mg/kg iv, loading dose + 7 hours continuous infusion) + lorazepam (L) (2.5 mg × 4 po) was compared with low-dose metoclopramide (LDM) (70 mg) + L (2.5 mg × 2 po) + dehydrobenzperidol (5 mg × 2 im). Among the 29 patients who completed the cross-over, HDM significantly reduced the number of vomiting episodes (p - 0.002) and the degree of nausea (p = 0.004). Seventeen patients preferred the HDM and 4 the LDM regimen (p= 0.01). Sedation was seen in all but 1 patient, and was graded as severe in 6 patients receiving the HDM and in 2 patients receiving the LDM regimen. No extrapyramidal adverse reactions were seen. We conclude that high-dose metoclopramide + lorazepam is a safe antiemetic regimen and significantly superior to low-dose metoclopramide + lorazepam + dehydrobenzperidol. Owing to the severe sedation which occurs in some patients, the dose of lorazepam should be individually adjusted.

    OriginalsprogEngelsk
    Sider (fra-til)223-227
    Antal sider5
    TidsskriftAnnals of Oncology
    Vol/bind2
    Udgave nummer3
    StatusUdgivet - 1 mar. 1991

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Original article: High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting' indeholder.

    Citationsformater